Holen Sie sich die Stockscreener-App
0.037
2.78%
0.001
Handel nachbörslich:
.04
0.003
+8.11%
Schlusskurs vom Vortag:
$0.036
Offen:
$0.0325
24-Stunden-Volumen:
6,345
Relative Volume:
3.77
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.09M
KGV:
-0.0511
EPS:
-0.7236
Netto-Cashflow:
$-321.00K
1W Leistung:
+2.78%
1M Leistung:
-57.52%
6M Leistung:
-57.52%
1J Leistung:
-97.18%
1-Tages-Spanne:
$0.0325
$0.0469
1-Wochen-Bereich:
$0.0325
$0.0469
52-Wochen-Spanne:
$0.032
$0.12
Bio Path Holdings Inc Stock (BPTH) Company Profile
Firmenname
Bio Path Holdings Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare BPTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.037 | 0 | 0 | -6.09M | -321.00K | -0.7236 |
VRTX
Vertex Pharmaceuticals Inc
|
468.42 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.03 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.40 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.18 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
169.51 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-11 | Eingeleitet | ROTH Capital | Buy |
| 2017-11-13 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-04-18 | Eingeleitet | Rodman & Renshaw | Buy |
| 2014-06-02 | Fortgesetzt | Maxim Group | Buy |
| 2014-05-09 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Bio Path Holdings Inc Aktie (BPTH) Neueste Nachrichten
RNA Interference Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Bio-Path: Q1 Earnings Snapshot - AOL.com
Bio-Path (OTC: BPTH) unveils crypto treasury plan and $57.9M judgment tie - Stock Titan
[15-12G] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
BIO-PATH HOLDINGS, INC. 1Q 2026: Revenue $0 Net loss $270K, EPS $(0.03) — 10-Q Summary - TradingView
BPTH: Net loss narrowed in Q1 2026 amid operational pause, but liquidity and going concern risks remain acute - TradingView
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cash-starved Bio-Path (OTCQB: BPTH) posts Q1 loss and massive dilution - Stock Titan
Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer - BioSpace
Bio-Path Holdings Delays Quarterly SEC Filing - TipRanks
Bio-Path (NASDAQ: BPTH) notifies SEC of late Q1 2026 10-Q filing - Stock Titan
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - The Manila Times
Oligonucleotides Clinical Trial Drug Development Pipeline - GlobeNewswire
BIO-PATH ANNOUNCES REPOSITIONING TO SUPPORT GROWTH, ADDS SCIENTIF - The National Law Review
BIO-PATH ANNOUNCES REPOSITIONING TO SUPPORT GROWTH, ADDS SCIENTIFIC ADVISORS, ENGAGES BANKERS, CANCELS REVERSE - EIN News
Stock Market Research, Data and Tools - GuruFocus
TTM Technologies, Inc. Files Amendment No. 1 to Form 8-K/A Announcing New Board Appointments – SEC Filing Details - Minichart
Standex International Corporation 2026 Q1 Financial Results and SEC Filing Overview - Minichart
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path - Barchart.com
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues - Yahoo Finance
Gossamer Bio downgraded by Cantor on unclear regulatory path for seralutinib - MSN
Leading Companies Consolidating Their Presence in the Antisense and RNAi Therapeutics Market - openPR.com
MSN Money - MSN
RNA Therapies Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Marginal Zone Lymphoma Clinical Trial Pipeline Expands as 50+ - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path Holdin - Barchart.com
Layoff Tracker: Replimune lays off over 200 in Massachusetts - BioSpace
XBP Global Holdings, Inc. (NASDAQ:XBP) Has Found A Path To Profitability - Yahoo Finance
5E Advanced Materials, Inc. Files Form 8-K with Nasdaq Listing Details and Emerging Growth Company Status - Minichart
In-Depth Examination of Segments, Industry Trends, and Key - openPR.com
Top News Today/Canada: Goods-Trade Deficit Widens, Surplus With U.S. Narrows - 富途牛牛
Microbot Medical Inc. (MBOT) stock price, news, quote and history - Yahoo Finance Australia
Stock List: Research Stocks from Around the World - GuruFocus
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Analyzing Bio-Path (BPTH) and Its Rivals - defenseworld.net
IXICO Taps Tech Bio Path with Strategic Medidata Deal - kalkinemedia.com
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
[1-A] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Shows Potential with Active Contributions from 70+ Key Companies | DelveInsight - Barchart.com
Bio-Path Holdings, Inc. Announces Domestication to Wyoming and Amendment Creating Series S Preferred Stock - Minichart
Bio-Path Holdings approves Wyoming move and creates new preferred stock class - Investing.com Australia
[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event - Stock Titan
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX) - Defense World
SEC Filings for Mar 19, 202610-K, 10-Q, 8-K Forms - Stock Titan
Gossamer Bio 2025 Annual Report: Seralutinib PAH Clinical Development, FDA Path, and Regulatory Strategy Insights - Minichart
Vuzix Reports 2025 Financial Results, Secures $20M Quanta Investment, and Advances Waveguide & OEM Smart Glasses Growth - Minichart
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ - openPR.com
Is Bio Path Holdings Inc. (IBP0) stock a defensive play amid uncertaintyQuarterly Trade Review & Long Hold Capital Preservation Plans - Naître et grandir
Finanzdaten der Bio Path Holdings Inc-Aktie (BPTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
Kapitalisierung:
|
Volumen (24h):